| Recruiting | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in th NCT07069699 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma NCT07168291 | First Affiliated Hospital Xi'an Jiaotong University | EARLY_Phase 1 |
| Recruiting | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab NCT07097363 | University of Washington | Phase 2 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies NCT05990465 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or NCT06395103 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Immunotherapy in Lymphoma NCT06796517 | Sung-Soo Park | — |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Recruiting | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine NCT06060782 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 1 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas NCT05389423 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880 | Medical College of Wisconsin | N/A |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Active Not Recruiting | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell NCT05270057 | Medical College of Wisconsin | Phase 1 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Unknown | GastroIntestinal Cancer in Children and Adolescents NCT05693519 | Paul G. Kemps, MD | — |
| Active Not Recruiting | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma NCT05263583 | Cothera Bioscience, Inc | Phase 2 |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Recruiting | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 NCT05518383 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 |
| Terminated | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell NCT04933617 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma NCT05020392 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Rel NCT04739813 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Recruiting | Recommendations for the Treatment of Children With Burkitt's Lymphoma NCT04425421 | French Africa Pediatric Oncology Group | — |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda NCT03864419 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment NCT03677128 | Duke University | N/A |
| Completed | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Recruiting | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT NCT03810196 | Children's Hospital of Philadelphia | N/A |
| Active Not Recruiting | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma NCT03223610 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells NCT03375619 | Medical College of Wisconsin | — |
| Unknown | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma NCT03298828 | Third Military Medical University | Phase 1 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk NCT02483000 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773 | University of Arizona | Phase 1 |
| Terminated | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas NCT02700022 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Withdrawn | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor NCT02776891 | University of California, San Francisco | Phase 2 |
| Recruiting | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL NCT02393157 | New York Medical College | Phase 2 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Completed | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma NCT01943682 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Completed | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diag NCT01793233 | Children's Oncology Group | — |
| Completed | A Phase I Trial of AZD3965 in Patients With Advanced Cancer NCT01791595 | Cancer Research UK | Phase 1 |
| Completed | A Safety Study of SGN-CD19A for Leukemia and Lymphoma NCT01786096 | Seagen Inc. | Phase 1 |
| Completed | A Safety Study of SGN-CD19A for B-Cell Lymphoma NCT01786135 | Seagen Inc. | Phase 1 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblasti NCT01363128 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy NCT01184885 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Terminated | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse L NCT01092182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) NCT00864227 | Medical College of Wisconsin | Phase 2 |
| Completed | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT NCT00849147 | Medical College of Wisconsin | Phase 2 |
| Completed | Coproporphyrine Isomers and Methotrexate Elimination NCT00822432 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma NCT00126191 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas NCT00183976 | University of Southern California | Phase 2 |
| Unknown | LMBA02 Protocol for Patients With a Burkitt Lymphoma NCT00180882 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Terminated | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL NCT00180895 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Completed | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lym NCT01290120 | Northern Italy Leukemia Group | Phase 2 |
| Completed | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lympho NCT00001337 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas NCT00001237 | National Cancer Institute (NCI) | Phase 2 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |